Stock comparison

ABBVvsINSM

AbbVie IncvsInsmed Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

ABBV

AbbVie Inc

$200.95

-12.05%

Biotechnology$362.8BNYSE

INSM

Insmed Inc

$144.48

-26.63%

Biotechnology$35.0BNASDAQ

60-day price, rebased to 100

ABBV -8.25% · INSM -8.45%

Round-by-round

ABBV 4·INSM 1· 1tie

EdgeABBV

Valuation upside

-48.60% vs -90.50% to DCF fair value

EdgeINSM

Balance-sheet strength

Altman Z 2.25 vs 9.81

EdgeABBV

Fundamental quality

Piotroski 7.00 vs 4.00 (of 9)

EdgeABBV

Growth + margins

Rule-of-40 37.70 vs -92.80

Tie

60-day momentum

-8.25% vs -8.45% price return

EdgeABBV

Market-cap liquidity

$362.8B vs $35.0B

Verdict

Across6categories,ABBVtakes the edge with4wins to1 (and 1 tie). Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onABBVorINSM

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.